---
title: "Lysergide (DT120) in Generalized anxiety disorder: Pharmacokinetics"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Pharmacokinetics. Topics: ODT versus capsule: relative bioavailability study design (MM-120-101); ODT versus capsule: published abstract results; ODT versus capsule: company analysis of pharmacokinetic parameters, March 2024; Formulation rationale stated by the sponsor; 8 further topics. 12 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### ODT versus capsule: relative bioavailability study design (MM-120-101)

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100μg with a new 100μg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”
> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study designed to compare the plasma PK profile of 2 MM120 formulations in healthy adults aged 18 to 55 years.”
> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.3-2"></a>

### ODT versus capsule: published abstract results

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”
> “MM120 ODT showed a faster onset of plasma concentrations than MM120 capsules, retaining similar relative bioavailability for Cmax.”
> “For AUC, the GMR for MM120 ODT was 16% higher compared with MM120 capsules.”
> “The ODT formulation had bioavailability similar to that of the capsule.”
> “ODT absorption occurred faster compared with capsules and there was a more rapid onset of acute drug effects in the ODT formulation.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### ODT versus capsule: company analysis of pharmacokinetic parameters, March 2024

| Parameter | MM120 capsule | MM120 ODT |
| --- | --- | --- |
| Tmax (hr) | “2.25” | “2.0” |
| Cmax (ng/mL) | “2.63” | “2.68” |
| AUC0-∞ (ng*hr/mL) | “15.7” | “18.7” |
| AUC>1ng/mL (ng*hr/mL) | “9.7” | “12.0” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

> “Company analysis of pharmacokinetic data from Study MM120-101. PK analysis based on n=24 subjects that completed both dosing sessions.”
> “50% faster onset of action”
> “17% improved bioavailability”
> “23% increase in AUC at target conc.”
> “Based on time to reach target concentration of >1 ng/mL.”
> “Based on comparison of geometric mean ratio of total area under the curve.”
> “Based on ratio of mean AUC>1ng/mL. Target concentrations defined as level above which perceptual effects are present.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-2.1.2.6.3-4"></a>

### Formulation rationale stated by the sponsor

> “DT120 ODT is an advanced formulation incorporating Catalent’s Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.6.3-5"></a>

### Food effect study of DT120 ODT: design

> “Phase 1 PK Food Effect (n = 64)”
> “Cohort 1: 100-μg ODT fasted vs high-fat meal”
> “Cohort 2: 100-μg ODT fasted vs low-fat meal”
> “Open-label, crossover in healthy volunteers”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.3-6"></a>

### Food effect study of DT120 ODT: treatment-emergent adverse events by cohort

| Measure | DT120 ODT + high-fat meal (n = 31) | DT120 ODT + low-fat meal (n = 28) |
| --- | --- | --- |
| Any TEAE | “31 (100.0)” | “28 (100.0)” |
| TEAE leading to treatment withdrawal | “1 (3.2)” | “2 (7.1)” |
| Mild | “24 (77.4)” | “22 (78.6)” |
| Moderate | “7 (22.6)” | “5 (17.9)” |
| Severe | “0” | “1 (3.6)” |
| Any related TEAE | “31 (100.0)” | “28 (100.0)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.3-7"></a>

### Food effect study of DT120 ODT: UK research ethics and registry records

> “Phase 1 PK study of MM-120 under fed and fasted conditions in healthy volunteers”
> “REC reference 24/WA/0003”
> “Date of REC Opinion 22 Mar 2024”

Source: [HRA Phase 1 PK study of MM-120 under fed and fasted conditions (2024)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-under-fed-and-fasted-conditions-in-healthy-volunteers/)

> “Phase I trial MM-120-102”
> “Approved 22/03/2024, Wales Research Ethics Committee 1”
> “ref: 24/WA/0003”
> “Phase I study in 32 healthy volunteers”
> “Non randomised study”
> “Completion date 29/08/2024”

Source: [ISRCTN ISRCTN15997848](https://www.isrctn.com/ISRCTN15997848)

<a id="topic-2.1.2.6.3-8"></a>

### Food effect: regulatory expectation for oral psychedelic drugs

> “Sponsors should evaluate the effect of a high-fat meal on the pharmacokinetics of an oral psychedelic drug early in development to inform clinical study design and potential labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.6.3-9"></a>

### Absorption, peak concentration, and half-life of oral LSD

> “Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6-2.0) and 3.4 ng/mL (3.0-3.8) after the administration of 85 and 170 μg LSD, respectively.”
> “Maximal concentrations were achieved on average after 1.7 h.”
> “Elimination half-lives were 3.7 h (3.4-4.1) and 4.0 h (3.6-4.4), for 85 and 170 μg LSD, respectively.”
> “LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2–1.9) and 3.1 (2.6–4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively.”
> “The plasma half-life was 2.6 h (2.2–3.4 h).”
> “Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

<a id="topic-2.1.2.6.3-10"></a>

### Absolute oral bioavailability and bioequivalence of LSD base and tartrate

> “We used a randomized, double‐blind, placebo‐controlled, five‐period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos.”
> “All oral formulations were bioequivalent, with the ethanolic base solution as a reference.”
> “The absolute bioavailability of oral LSD was 80% and similar for all tested formulations.”
> “In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.”

Source: [Arikci et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12355019/)

<a id="topic-2.1.2.6.3-11"></a>

### Metabolism and urinary excretion

> “Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.”
> “LSD is extensively metabolized and shows dose-proportional urinary recovery.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Plasma O‐H‐LSD but not nor‐LSD (< 0.01 ng/mL) concentrations could be quantified in all subjects.”

Source: [Holze et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6595343/)

<a id="topic-2.1.2.6.3-12"></a>

### Cytochrome P450 enzymes in LSD metabolism

> “CYP2D6, 2E1, and 3A4 significantly contributed to the formation of nor-LSD, and CYP1A2, 2C9, 2E1, and 3A4 were significantly involved in the formation of O-H-LSD.”
> “To conclude, human liver microsomes converted only small amounts of LSD to nor-LSD and O-H-LSD but several CYPs significantly contributed.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

> “Thus, CYP2D6 is likely a crucial player in the degradation of LSD but not in the formation of its main metabolite O-H-LSD.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
